{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:24:25Z","timestamp":1777922665951,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2013,8]]},"abstract":"<jats:p>\n                    The objectives of this study were to evaluate the clinical effectiveness of gentamicin as an initial empirical antimicrobial agent and to determine the effects of gentamicin resistance on clinical outcomes in women with uncomplicated acute pyelonephritis (APN). We analyzed data of 2,033 women with a diagnosis of APN admitted to Catholic University St. Vincent's Hospital. Of those, we enrolled 274 cases of community-acquired uncomplicated APN due to\n                    <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                    who received gentamicin as initial antibiotics. Of these 274 patients, 47 patients had gentamicin-resistant (GM-R)\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    APN, and 227 patients had gentamicin-susceptible (GM-S)\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    APN. The early clinical response rates were 55.3% (26\/47) versus 81.5% (185\/227) at 72 hours; 61.7% (29\/47) versus 96.9% (220\/227) at 96 hours in the GM-R and GM-S groups, which was significantly higher in the GM-S group (\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    &lt;0.001). Overall clinical cure rates were 100% (47\/47) and 99.6% (226\/227) in the GM-R and GM-S groups, respectively. APN patients in the GM-R group had longer hospitalization (9.72\u00b13.46 and 7.89\u00b12.27 days;\n                    <jats:italic toggle=\"yes\">p<\/jats:italic>\n                    &lt;0.001) than those in the GM-S group. Resistance of\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    to gentamicin, bacteremia, and C-reactive protein level showed independent effects on early clinical failure. Aminoglycoside such as gentamicin can be an alternative antibiotic option for initial empirical therapy of community-acquired uncomplicated APN as the fluoroquinolone-sparing or broad-spectrum cephalosporin-sparing agents in an era of increasing antimicrobial resistance, especially in areas where medical resources are limited or antibiotic resistance rate of the uropathogens is high.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2012.0140","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T09:54:20Z","timestamp":1362736460000},"page":"316-322","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Use of Gentamicin for Women with Community-Acquired Uncomplicated Acute Pyelonephritis Caused by Gentamicin-Susceptible or -Resistant\n                    <i>Escherichia coli:<\/i>\n                    10-Year Experience"],"prefix":"10.1177","volume":"19","author":[{"given":"Seong-Heon","family":"Wie","sequence":"first","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyung Wook","family":"Kim","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U-Im","family":"Chang","sequence":"additional","affiliation":[{"name":"The Catholic University of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,8]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2010.11.2217"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0255-0857(21)02465-8","article-title":"ESBL- from petri dish to the patient","volume":"24","author":"Bhattacharya S.","year":"2006","unstructured":"Bhattacharya S. 2006. ESBL- from petri dish to the patient. Indian J. Med. Microbiol., 24:20\u201324.","journal-title":"Indian J. Med. Microbiol."},{"key":"e_1_3_2_4_2","first-page":"MI00","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: 15th Informational Supplement: Approved Standard","author":"[CLSI] Clinical, Laboratory Standard Institute","year":"2005","unstructured":"[CLSI] Clinical, Laboratory Standard Institute. 2005. Performance Standards for Antimicrobial Susceptibility Testing: 15th Informational Supplement: Approved Standard. Wayne, PA, MI00\u2013S15."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)65134-3"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0924-8579(03)00238-3","article-title":"Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection","volume":"22","author":"Hooton T.M.","year":"2003","unstructured":"Hooton T.M. 2003. Fluoroquinolones and resistance in the treatment of uncomplicated urinary tract infection. Int. J. Antimicrob. Agents, 22:565\u2013572.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0924-8579(03)00229-2","article-title":"Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study","volume":"22","author":"Kahlmeter G.","year":"2003","unstructured":"Kahlmeter G. 2003. Prevalence and antimicrobial susceptibility of pathogens in uncomplicated cystitis in Europe. The ECO.SENS study. Int. J. Antimicrob. Agents, 22S:S49\u2013S52.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijantimicag.2011.09.013","article-title":"Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO\u00b7SENS study revisited","volume":"39","author":"Kahlmeter G.","year":"2012","unstructured":"Kahlmeter G., , Poulsen H.O. 2012. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO\u00b7SENS study revisited. Int. J. Antimicrob. Agents, 39:45\u201351.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1128\/AAC.00066-11","article-title":"Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study","volume":"55","author":"Karlowsky J.A.","year":"2011","unstructured":"Karlowsky J.A., , Lagace-Wiens P.R., , Simner P.J., , DeCorby M.R., , Adam H.J., , Walkty A., , Hoban D.J., , Zhanel G.G. 2011. Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study. Antimicrob. Agents Chemother., 55:3169\u20133175.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ijantimicag.2007.07.043","article-title":"Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006","volume":"31","author":"Kim M.E.","year":"2008","unstructured":"Kim M.E., , Ha U.S., , Cho Y.H. 2008. Prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in female outpatients in South Korea: a multicentre study in 2006. Int. J. Antimicrob. Agents, 31S:S15\u2013S18.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/AAC.43.5.1020","article-title":"Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administration","volume":"43","author":"Lebrun M.","year":"1999","unstructured":"Lebrun M., , Grenier L., , Gourde P., , Bergeron M.G., , Labrecque G., , Beauchamp D. 1999. Effectiveness and toxicity of gentamicin in an experimental model of pyelonephritis: effect of the time of administration. Antimicrob. Agents Chemother., 43:1020\u20131026.","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3349\/ymj.2012.53.1.164","article-title":"Change of antimicrobial susceptibilities among Escherichia coli strains isolated from female patients with community-onset acute pyelonephritis","volume":"53","author":"Lim S.K.","year":"2012","unstructured":"Lim S.K., , Park I.W., , Lee W.G., , Kim H.K., , Choi Y.H. 2012. Change of antimicrobial susceptibilities among Escherichia coli strains isolated from female patients with community-onset acute pyelonephritis. Yonsei Med. J., 53:164\u2013171.","journal-title":"Yonsei Med. J."},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.71-76.2005"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc5713"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0924-8579(01)00481-2","article-title":"Piperacillin 2\u2009g\/tazobactam 0.5\u2009g is as effective as imipenem 0.5\u2009g\/cilastatin 0.5\u2009g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections","volume":"19","author":"Naver K.G.","year":"2002","unstructured":"Naver K.G., , Savov O., , Salmen H.C. 2002. Piperacillin 2\u2009g\/tazobactam 0.5\u2009g is as effective as imipenem 0.5\u2009g\/cilastatin 0.5\u2009g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Int. J. Antimicrob. Agents, 19:95\u2013103.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1464-410X.2006.06222.x","article-title":"Risk factors for a poor outcome after therapy for acute pyelonephritis","volume":"98","author":"Pertel P.E.","year":"2006","unstructured":"Pertel P.E., , Haverstock D. 2006. Risk factors for a poor outcome after therapy for acute pyelonephritis. BJU. Int., 98:141\u2013147.","journal-title":"BJU. Int."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki166"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1086\/649537","article-title":"Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis","volume":"50","author":"Rodriguez-Bano J.","year":"2010","unstructured":"Rodriguez-Bano J., , Picon E., , Gijon P., , Hernandez J.R., , Ruiz M., , Pena C., , Almela M., , Almirante B., , Grill F., , Colomina J., , Gimenez M., , Oliver A., , Horcajada J.P., , Navarro G., , Coloma A., , Pascual A. Spanish Network for Research in Infectious Diseases (REIPI). 2010. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis. Clin. Infect. Dis., 50:40\u201348.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0891-5520(05)70374-3","article-title":"Complicated urinary tract infections","volume":"11","author":"Ronald A.R.","year":"1997","unstructured":"Ronald A.R., , Harding G.K. 1997. Complicated urinary tract infections. Infect. Dis. Clin. North Am., 11:583\u2013592.","journal-title":"Infect. Dis. Clin. North Am."},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0002-9343(88)80023-8","article-title":"Pyelonephritis in adult women: inpatient versus outpatient therapy","volume":"85","author":"Safrin S.","year":"1988","unstructured":"Safrin S., , Siegel D., , Black D. 1988. Pyelonephritis in adult women: inpatient versus outpatient therapy. Am. J. Med., 85:793\u2013798.","journal-title":"Am. J. Med."},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/adc.2007.121079","article-title":"Is a once daily dose of gentamicin safe and effective in the treatment of uti in infants and children?","volume":"92","author":"Shahid M.","year":"2007","unstructured":"Shahid M., , Cooke R. 2007. Is a once daily dose of gentamicin safe and effective in the treatment of uti in infants and children? Arch. Dis. Child., 92:823\u2013824.","journal-title":"Arch. Dis. Child."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2011.0139"},{"key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jama.283.12.1583","article-title":"Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial","volume":"283","author":"Talan D.A.","year":"2000","unstructured":"Talan D.A., , Stamm W.E., , Hooton T.M., , Moran G.J., , Burke T., , Iravani A., , Reuning-Scherer J., , Church D.A. 2000. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. JAMA, 283:1583\u20131590.","journal-title":"JAMA"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp330"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.3.430-450.2003"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ijantimicag.2010.05.005","article-title":"Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterization","volume":"36","author":"van Nieuwkoop C.","year":"2007","unstructured":"van Nieuwkoop C., , den Exter P.L., , Elzevier H.W., , den Hartigh J., , van Dissel J.T. 2007. Intravesical gentamicin for recurrent urinary tract infection in patients with intermittent bladder catheterization. Int. J. Antimicrob. Agents, 36:485\u2013490.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2334-11-187","article-title":"Unnecessary use of fluoroquinolone antibiotics in hospitalized patients","volume":"11","author":"Werner N.L.","year":"2011","unstructured":"Werner N.L., , Hecker M.T., , Sethi A.K., , Donskey C.J. 2011. Unnecessary use of fluoroquinolone antibiotics in hospitalized patients. BMC Infect. Dis., 11:187.","journal-title":"BMC Infect. Dis."},{"key":"e_1_3_2_30_2","volume-title":"Clinical Microbiology Procedures Handbook","author":"York M.K.","year":"2004","unstructured":"York M.K. 2004. Aerobic bacteriology. Isenberg H.D. Clinical Microbiology Procedures Handbook, 2nd. ASM Press: Washington, DC, 3.12.1\u20133.12.15.","edition":"2"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2012.0140","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2012.0140","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2012.0140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:27:23Z","timestamp":1777667243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/mdr.2012.0140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["10.1089\/mdr.2012.0140"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2012.0140","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}